Clinical Sales Specialist

Senseonics' in-house distribution bet pays off with record revenue, profitability still distant. Record CGM sales drive Senseonics' revenue, but the path to profitability remains unclear. Omar Ford, Editor-in-Chief, MD+DI, Informa Markets - Engineering August 7, 2026 At a glance. * Senseonics reported 2Q26 revenue of $14.5 million, beating expectations. * Net loss widened to $36.7 million from $14.5 million year-over-year. * Senseonics resumed direct distribution of its CGM products a year ago. Senseonics Holdings is seeing strong earnings growth from distributing its diabetes products and year-long continuous glucose monitor (CGM). The Germantown, MD-based company reported 2Q26 revenue of $14.5 million, beating the consensus of $13.4 million. BTIG analysts said that revenue grew more than 150%, representing the "highest quarterly shipment volume in company history." Senseonics momentum surge can be traced back a year ago when it announced it would resume direct distribution of the Eversense CGM products. Ascensia Diabetes Care, a Basel, Switzerland-based company, held the exclusive worldwide distribution rights for the Eversense CGMs since 2020. Senseonics President, CEO and Director Tim Goodnow said, "Coming into the year, our thesis was that bringing the commercial organization fully in-house, combined with the strength of Eversense 365, would unlock durable revenue growth and margin expansion," according to a Seeking Alpha transcript of the call. "And so far, we see this thesis is playing out ahead of expectations." In response to the strong earnings, Senseonics raised 2026 full-year revenue guidance to $62 million to $66 million. Previous guidance was set at $60 million to $64 million. Redefining CGM in a competitive market. Part of the company's plan to redefine CGMs for users came in September of 2014 when Senseonics won FDA clearance for Eversense 365, a year-long CGM system. The clearance came during a time when the CGM market was teeming with innovation. At the time, Medtronic and Abbott had announced a collaboration to develop an integrated continuous glucose monitoring system (CGM) based on the FreeStyle Libre technology. Abbott remained busy - and secured a nod from FDA for an over-the-counter CGM. Dexcom would obtain FDA clearance for an OTC CGM, too. However, Senseonics touted Eversense 365 as the first year-long CGM system, designed to minimize the frequency of sensor replacements and provide consistent, long-term glucose monitoring. "We're redefining what a CGM can be for people with diabetes," Goodnow said, according to a Seeking Alpha transcript of the earnings call. The march toward profitability. Despite growth in revenue, the company's net loss grew from $14.5 million in the prior year period to about $36.7 million in 2Q26. The increase in loss was chalked up to increased SG&A and R&D expenses. The firm also has high operating expenses, which range from $150 to $160 million for a year, which, according to an article from GuruFocus, "suggests the company is still in a heavy investment phase with no near-term profitability." BTIG Analyst Marie Thibault wrote, "We continue to be encouraged by the positive commercial momentum from Eversense 365 and the company's ability to consistently beat and raise, though we continue to await further clarity on the eventual path to profitability." Editor-in-Chief, MD+DI, Informa Markets - Engineering Omar Ford is a seasoned journalist specializing in medical technology, healthcare innovation, and the medical device and diagnostics industry. As the editor-in-chief of Medical Device + Diagnostics Industry (MD+DI), he has earned a reputation as a leading authority in the field, offering in-depth insights into the latest trends, regulatory changes, and technological advancements shaping the future of healthcare. Omar has been a featured speaker at MD&M and MEDevice events. Omar has written for several publications prior to MD+DI. He is a former contributor at Bioworld Medtech, an online publication owned by Clarivate. He was a general assignment reporter for the Beaufort Gazette and an education and county reporter for the Griffin Daily News. He is the 2001 winner of the Judson Chapman Award from the South Carolina Press Association and the 2003 McClatchy President's Award recipient. Omar has a bachelor's degree in print journalism from the University of South Carolina. Throughout his tenure at MD+DI, Omar has covered a wide array of topics, including medical technology innovations, regulatory affairs, market dynamics, and the growing impact of artificial intelligence in healthcare. Omar is the host of the Let's Talk Medtech podcast. Want more MD+DI in your search results?

Amani Aljuaid: driving Human Capital Strategy and Organizational Transformation at Siemens Healthineers Saudi Arabia. Strong organizations are built on more than products, services or technology; they are built on people. Behind every successful business transformation is a leadership team capable of aligning talent, culture and strategy to deliver sustainable growth. At Siemens Healthineers Saudi Arabia, Amani Aljuaid is helping shape that future through a people-first approach to leadership, organizational development and workforce transformation. As Country Head of HR, Aljuaid leads the company's human resources strategy across Saudi Arabia, supporting Siemens Healthineers' mission to advance healthcare and improve patient outcomes. Her responsibilities span the full employee lifecycle, from workforce planning and leadership development to organizational transformation, performance management, talent acquisition and employee engagement. Working across both the company's in vivo and in vitro business lines, she partners closely with executive leadership to ensure people strategies directly support business priorities while remaining aligned with Saudi Arabia's Vision 2030 ambitions, Saudization initiatives and global corporate standards. Building organizations through strategic HR leadership. With more than 14 years of experience across American, Norwegian and German multinational organizations, Aljuaid has established herself as a strategic HR leader with expertise in navigating complex organizational change. Her leadership extends well beyond traditional human resources management. Throughout her career, she has led localization initiatives, organizational redesign projects, leadership capability development, culture transformation programmes and business expansion strategies, helping organizations adapt to changing market environments while strengthening employee experience and organizational performance. Her work is centred on connecting people with purpose - ensuring that business strategy, leadership capability and workplace culture evolve together to create resilient, future-ready organizations. Leading transformation across global healthcare organizations. Before joining Siemens Healthineers, Aljuaid spent more than eight years at Abbott, progressing through a series of increasingly senior leadership positions. She most recently served as Human Resources Director, where she led strategic HR transformation initiatives while partnering with executive leadership to strengthen organizational effectiveness, succession planning, workforce capability and employee engagement. Prior to that, she served as Head of Human Resources, where she established the company's HR function from the ground up, developing end-to-end people processes, organizational policies and talent strategies that supported long-term business growth. Earlier roles as Talent Acquisition Manager and Senior Talent Acquisition Specialist further strengthened her expertise in executive hiring, workforce planning, employer branding and talent management. Her career also includes nearly four years with Jotun, where she gained experience across both human resources and commercial operations, providing a broad understanding of organizational performance from multiple business perspectives. Developing future-ready organizations. Throughout her career, Aljuaid has championed initiatives that strengthen leadership capability, improve employee experience and foster inclusive workplace cultures. Her expertise spans: * Human Capital Strategy * Organizational Development * Leadership Development * Talent Acquisition & Succession Planning * Workforce Planning * Organizational Transformation * Change Management * Employee Engagement * Diversity & Inclusion * Performance Management * HR Governance * Strategic Business Partnership By combining international HR best practices with a deep understanding of Saudi Arabia's evolving business landscape, she continues to help organizations develop agile workforces capable of supporting long-term growth. Academic foundation and executive development. Aljuaid holds a Master of Business Administration (MBA) in Human Resources from the University of Business & Technology, following a Bachelor's degree in International Business from King Abdulaziz University. She has also completed the Women Leaders Program at INSEAD, further strengthening her executive leadership capabilities in strategic planning, organizational leadership, influence and change management. Her continued investment in executive education reflects her commitment to building high-performing organizations through thoughtful leadership and people development. Shaping the future of HR leadership. As Saudi Arabia continues investing in healthcare innovation, workforce localization and economic diversification under Vision 2030, strategic HR leadership has become increasingly important in helping organizations navigate change while attracting, developing and retaining exceptional talent. Through her work at Siemens Healthineers, Amani Aljuaid continues to demonstrate how human capital strategy can become a competitive advantage - creating workplaces where business transformation and employee success grow together.

FDA approves SimpleScreen(TM) CRC blood test for colorectal cancer screening in average-risk adults. The approval provides adults aged 45 years and older at average risk of colorectal cancer with an additional blood-based screening option, expanding access for individuals who are overdue for screening. The US Food and Drug Administration (FDA) has approved SimpleScreen(TM) CRC, Freenome's blood-based colorectal cancer screening test, for adults aged 45 years and older who are at average risk of the disease, marking the company's first commercial product. The approval expands the range of screening options available for eligible patients and may help increase screening uptake among individuals who are reluctant to undergo stool-based testing or colonoscopy, while not replacing established diagnostic pathways. | Field | Content | | Alert Type | Drug Approval | | Drug Name | SimpleScreen(TM) CRC | | Indication | Blood-based screening for colorectal cancer in adults aged 45 years and older who are at average risk of colorectal cancer. | | Therapy Area(s) | Oncology; Gastroenterology | | Geography | US (FDA) | | What Happened | The FDA approved SimpleScreen(TM) CRC on 27 July 2026 for colorectal cancer screening in adults aged 45 years and older who are at average risk of the disease. The approval gives Freenome its first FDA-approved commercial product and authorises Abbott, which holds exclusive US commercialisation rights, to launch the blood-based screening test in the US. The approval expands the range of FDA-authorised blood-based colorectal cancer screening options available for average-risk adults. | | Why It Matters | The approval provides clinicians and eligible patients with an additional non-invasive colorectal cancer screening option. While blood-based testing does not replace colonoscopy or other recommended diagnostic pathways, it may improve participation among people who remain unscreened, helping to broaden access to recommended colorectal cancer screening. | | Supporting Context | Colorectal cancer is the second leading cause of cancer-related death in the United States. Freenome estimates that up to 60 million eligible Americans are overdue for colorectal cancer screening, highlighting the need for additional screening options. | | Key Takeaway | FDA approval of SimpleScreen(TM) CRC expands the range of blood-based colorectal cancer screening options available for average-risk adults aged 45 years and older. | | What to Watch | Abbott plans to commercially launch SimpleScreen(TM) CRC in the United States during autumn 2026. Uptake, reimbursement and future updates to clinical screening recommendations will be important to monitor. | | Primary Source | https://investors.freenome.com/news-releases/news-release-details/fda-approves-freenomes-simplescreentm-crc-blood-based-screening | | Relevant Date | 27 July 2026 | Discover how nuaxia can support your next medical education initiative: